Radiation Therapy for Medulloblastoma
David Harris(Merck & Co., Inc., Rahway, NJ, USA (United States)), Paul Rava(UMass Memorial Health Care), Julie Trifone, Eric C. Ko(UMass Memorial Health Care), Yansong Geng, Jessica Yancey, Maryann Bishop‐Jodoin(Health Insurance Review and Assessment Service), Linda Ding(University of Massachusetts Chan Medical School), Gavin W. Jones(National University of Singapore), Koren Smith(University of Massachusetts Chan Medical School), Matthew Iandoli(Calista Therapeutics (United States)), Fran Laurie(University of Massachusetts Chan Medical School), Sandy Kessel(Providence College), Julia Hayden
Cited by 3
Related Papers
Radiation Field Design in the ACOSOG Z0011 (Alliance) Trial
|Journal of Clinical Oncology|2014|394
Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma—a report from the IRSG 1 1For a complete list of the members of the Children’s Oncology Group Soft Tissue Sarcoma Committee (formerly Intergroup Rhabdomyosarcoma Group) representing the Children’s Oncology Group and the Quality Assurance Review Center, see the Appendix.
|International Journal of Radiation Oncology*Biology*Physics|2001|213
A multidisciplinary study investigating radiotherapy in Ewing’s sarcoma: end results of POG #8346
|International Journal of Radiation Oncology*Biology*Physics|1998|207
A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children's Oncology Group prospective study
|The Lancet Oncology|2019|182
Local Control in Pelvic Ewing Sarcoma: Analysis From INT-0091—A Report From the Children's Oncology Group
|Journal of Clinical Oncology|2006|156